Metformin glycinate | CAS# 121369-64-0 | Biochemical

MedKoo Cat#: 577236 | Name: Metformin glycinate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Metformin glycinate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Chemical Structure

Metformin glycinate

CAS#121369-64-0 (glycinate)

Theoretical Analysis

MedKoo Cat#: 577236

Name: Metformin glycinate

CAS#: 121369-64-0 (glycinate)

Chemical Formula: C6H16N6O2

Exact Mass: 204.1335

Molecular Weight: 204.23

Elemental Analysis: C, 35.29; H, 7.90; N, 41.15; O, 15.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1115-70-4 (HCl) 657-24-9 (free base) 121369-64-0 (glycinate) 34461-22-8 ( embonate) 58840-24-7 (orotate) 1384526-74-2 (icosapent)

Synonym

Metformin glycinate

IUPAC/Chemical Name

N,N-Dimethyl-1,2,3-triimidodicarbonic diamide glycinate (1:1)

InChi Key

KOFRCHIVYXPUNL-UHFFFAOYSA-N

InChi Code

InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5)

SMILES Code

CN(C)C(=N)NC(=N)N.NCC(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 204.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sutter A, Landis D, Nugent K. Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis. Indian J Tuberc. 2024 Jan;71(1):89-95. doi: 10.1016/j.ijtb.2023.05.011. Epub 2023 May 16. PMID: 38296396. 2: Kelleni MT. Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach. Inflammopharmacology. 2024 Jan 31. doi: 10.1007/s10787-023-01421-8. Epub ahead of print. PMID: 38294616. 3: Wang Q, Wei X. Research Progress on the Use of Metformin in Leukemia Treatment. Curr Treat Options Oncol. 2024 Jan 30. doi: 10.1007/s11864-024-01179-3. Epub ahead of print. PMID: 38286894. 4: Pedreañez A, Carrero Y, Vargas R, Hernandez-Fonseca JP, Mosquera-Sulbaran J. Paolo Brambilla, PhD, MD Possible role of metformin as an antidepressant in diabetes. Review. J Affect Disord. 2024 Jan 27:S0165-0327(24)00247-7. doi: 10.1016/j.jad.2024.01.228. Epub ahead of print. PMID: 38286229. 5: Xie H, Li M, Zheng Y. Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis. Gynecol Oncol. 2024 Jan 20;182:15-23. doi: 10.1016/j.ygyno.2024.01.007. Epub ahead of print. PMID: 38246042. 6: Dewangga R, Winston K, Ilhami LG, Indriani S, Siddiq T, Adiarto S. Association of metformin use with abdominal aortic aneurysm: A systematic review and meta-analysis. Asian Cardiovasc Thorac Ann. 2024 Jan 18:2184923231225794. doi: 10.1177/02184923231225794. Epub ahead of print. PMID: 38239055. 7: Pujalte-Martin M, Belaïd A, Bost S, Kahi M, Peraldi P, Rouleau M, Mazure NM, Bost F. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024 Jan 12. doi: 10.1002/1878-0261.13583. Epub ahead of print. PMID: 38214418. 8: Almeida-Nunes DL, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins. Int J Mol Sci. 2023 Dec 25;25(1):323. doi: 10.3390/ijms25010323. PMID: 38203494; PMCID: PMC10779012. 9: Alatawi AM. Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis. Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):209-213. doi: 10.12669/pjms.40.1.6982. PMID: 38196460; PMCID: PMC10772430. 10: Ruan G, Wu F, Shi D, Sun H, Wang F, Xu C. Metformin: update on mechanisms of action on liver diseases. Front Nutr. 2023 Dec 14;10:1327814. doi: 10.3389/fnut.2023.1327814. PMID: 38192642; PMCID: PMC10773879. 11: Zhao D, Sohouli MH, Rohani P, Fotros D, Velu P, Ziamanesh F, Fatahi S, Shojaie S, Li Y. The effect of metformin on adipokines levels: A systematic review and meta-analysis of randomized-controlled trials. Diabetes Res Clin Pract. 2023 Dec 26;207:111076. doi: 10.1016/j.diabres.2023.111076. Epub ahead of print. PMID: 38154535. 12: Sacco M, Ribaldone DG, Saracco GM. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction? Viruses. 2023 Dec 17;15(12):2451. doi: 10.3390/v15122451. PMID: 38140692; PMCID: PMC10748230. 13: Isop LM, Neculau AE, Necula RD, Kakucs C, Moga MA, Dima L. Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders. Pharmaceuticals (Basel). 2023 Dec 11;16(12):1714. doi: 10.3390/ph16121714. PMID: 38139841; PMCID: PMC10748332. 14: Rittenhouse BE, Alolayan S, Eguale T, Segal AR, Doucette J. The cost- effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply. Prev Med. 2024 Jan;178:107819. doi: 10.1016/j.ypmed.2023.107819. Epub 2023 Dec 11. PMID: 38092328. 15: Cho M, Woo YR, Cho SH, Lee JD, Kim HS. Metformin: A Potential Treatment for Acne, Hidradenitis Suppurativa and Rosacea. Acta Derm Venereol. 2023 Dec 11;103:adv18392. doi: 10.2340/actadv.v103.18392. PMID: 38078688; PMCID: PMC10726377. 16: Chang W, Li W, Li P. The anti-diabetic effects of metformin are mediated by regulating long non-coding RNA. Front Pharmacol. 2023 Nov 20;14:1256705. doi: 10.3389/fphar.2023.1256705. PMID: 38053839; PMCID: PMC10694297. 17: Li R, Li H, Yang Z, Zhang X. Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Sept 28;48(9):1425-1431. English, Chinese. doi: 10.11817/j.issn.1672-7347.2023.230100. PMID: 38044655. 18: Tiwari A, Kumar Singh R, Satone PD, Meshram RJ. Metformin-Induced Vitamin B12 Deficiency in Patients With Type-2 Diabetes Mellitus. Cureus. 2023 Oct 26;15(10):e47771. doi: 10.7759/cureus.47771. PMID: 38034222; PMCID: PMC10688235. 19: Huang Z, Li J, Chen H, Yu D, Sun S. The efficacy of metformin for the treatment of psoriasis: a meta-analysis study. Postepy Dermatol Alergol. 2023 Oct;40(5):606-610. doi: 10.5114/ada.2023.130524. Epub 2023 Aug 22. PMID: 38028405; PMCID: PMC10646712. 20: Lin H, Ao H, Guo G, Liu M. The Role and Mechanism of Metformin in Inflammatory Diseases. J Inflamm Res. 2023 Nov 23;16:5545-5564. doi: 10.2147/JIR.S436147. PMID: 38026260; PMCID: PMC10680465.